Ibandronate sodium NDC 50090-7654

NDC codes

FDA NDC Directory

Product NDC (as listed)50090-7654Labeler and product segments. Claims need a package NDC.

Product NDC at billing width50090-7654Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
50090-7654-0	50090765400	1 BLISTER PACK in 1 CARTON (50090-7654-0) / 3 TABLET in 1 BLISTER PACKMarketed from Sep 17, 2025

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Ibandronate sodium
Generic name (nonproprietary): ibandronate sodium
Active ingredients: Ibandronate sodium — 150 mg/1
Dosage form: Tablet
Route: Oral
Labeler: A-S Medication Solutions
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 078997
Marketing start: Jun 21, 2012
Listing expires: Dec 31, 2026
Other FDA classes: Diphosphonates (Chemical structure)
Identifiers: Product ID 50090-7654_1b55f284-94ab-46b3-bb1b-0ef5746bb901SPL ID 1b55f284-94ab-46b3-bb1b-0ef5746bb901SPL set ID e5b6c2a9-a55f-41f9-a592-e26ef03e2d73RxCUI 904932UNII J12U072QL0
Pharmacologic class: Bisphosphonate

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N450090765400 followed by a unit qualifier and the quantity

Package 50090-7654-00. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Sep 22, 2025.

Indications (excerpt from the label)

Ibandronate sodium tablet is a bisphosphonate indicated for the treatment and prevention of postmenopausal osteoporosis. (1.1) Limitations of Use The optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use. (1.2). 1.1 Treatment and Prevention of Postmenopausal Osteoporosis Ibandronate sodium tablets are indicated for the treatment and prevention of osteoporosis in postmenopausal women. Ibandronate sodium tablets increases bone mineral density (BMD) and reduces the incidence of vertebral fractures. 1.2 Important Limitations of Use The optimal duration of use has not been determined. The safety and effectiv…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 078997

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 078997
Product	Strength	Form · route	Labeler	Product NDC
Ibandronate sodium	Ibandronate sodium 150 mg/1	TabletOral	Dr. Reddy's Laboratories Limited	55111-575